Nanobiotix (NASDAQ:NBTX, Euronext:NANO) announced that trading of its ordinary shares on Euronext Paris will resume on May 21, 2026 at 3:30 p.m. Paris time.
Trading was halted earlier that day at the company’s request, linked to a previously announced Global Offering of ADSs, ordinary shares, and pre-funded warrants.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – NBTX
-6.90%
13 alerts
-6.90%Session close to close
+4.6%Peak Tracked
-5.1%Trough Tracked
$2.09BMarket Cap
0.7xRel. Volume
In the May 21 session, NBTX declined 6.90%, reflecting a notable negative market reaction.
Argus tracked a peak move of +4.6% during that session.
Argus tracked a trough of -5.1% from its starting point during tracking.
Our momentum scanner triggered 13 alerts that day, indicating notable trading interest and price volatility.
The stock moved -6.9% in the session following this news. A negative reaction despite the resumption...
Analysis
The stock moved -6.9% in the session following this news. A negative reaction despite the resumption of trading fits a scenario where investors focused on dilution and balance-sheet optics around the planned €75,000,000 global offering. Pre-news, the stock sat about 24.47% below its 52-week high but far above its $3.64 low, leaving room for profit-taking. Past episodes show occasional sell-offs on good clinical updates, suggesting that financing-related concerns and existing gains could have outweighed recent positive data.
Key Figures
Global offering size:€75,000,000Warrant exercise price:€0.03Cash and equivalents:€52.8M+5 more
8 metrics
Global offering size€75,000,000Target size of global offering in 424B5 prospectus
Warrant exercise price€0.03Exercise price per ordinary share for pre-funded warrants
Cash and equivalents€52.8MReported as of December 31, 2025 in 424B5
Net tangible book deficit€(84.5M)As of December 31, 2025 in 424B5
Current share price$43.16Price before this trading resumption announcement
52-week high$57.1452-week high before this news
52-week low$3.6452-week low before this news
Shares outstanding48,517,630Share count as of March 31, 2026 from prior disclosure
2025 results showed €32.6M revenue and a sharply reduced €24.0M net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Positive clinical and financial updates often saw mixed reactions, with some notable divergences on good news.
Recent Company History
Over recent months, Nanobiotix reported multiple advances, including strong early CONVERGE Phase 2 data in lung cancer and an FDA-accepted protocol amendment for the pivotal NANORAY-312 Phase 3 trial, which previously coincided with a 11.59% gain. Preclinical Nanoprimer data and routine share-capital disclosures drew smaller, mixed moves. Full-year 2025 results, highlighted by €32.6M revenue and a narrowed €24.0M net loss, were followed by a 10.37% rise. Against this backdrop, the trading halt and resumption occur alongside a new equity offering that adds a capital-raising layer to prior clinical and financial progress.
Key Terms
american depositary shares, ads, pre-funded warrants, qualified investors, +1 more
5 terms
american depositary sharesfinancial
"a public offering of its American Depositary Shares (“ADSs”), each ADS representing"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
adsfinancial
"a public offering of its American Depositary Shares (“ADSs”), each ADS representing"
Ads are paid promotional messages a company places across media — online, on TV, in print, or on social platforms — to attract customers, explain products, or shape public perception. For investors, ads matter because they drive sales growth, affect how much a company must spend to win customers, and influence brand strength and long-term value. Ads can also create regulatory or reputational risk if claims are misleading, which can affect profits and stock price.
pre-funded warrantsfinancial
"an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
qualified investorsregulatory
"pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe"
Qualified investors are individuals or institutions that meet regulatory standards—such as a minimum income, net worth, or professional expertise—allowing them access to investment opportunities not open to the general public. Think of them as a financial "VIP" group: they can buy private deals, complex products, or early-stage securities that may offer higher returns but also carry greater risk and less public information, so their status matters because it changes what investments are available and what protections apply.
regulation (eu) 2017/1129regulatory
"within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended"
An EU law that sets uniform rules for the detailed disclosure document companies must give when offering securities to the public or listing them on markets. It matters to investors because it forces issuers to present a clear, standardized “label” of information—risks, business model, finances and terms—so you can compare offerings and spot missing or misleading claims. Think of it as a required ingredient list and instructions for financial products sold across the EU.
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).
Trading of the ordinary shares of the Company was halted at the request of the Company on May 21, 2026 from 9:00 a.m. CEST in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “International Offering” and, together with the U.S. Offering, the “Global Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States), amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
Contacts
Nanobiotix
Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com
Global – uncapped Communications Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com
Disclaimers
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of such securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
When did Nanobiotix (NBTX) resume trading on Euronext Paris on May 21, 2026?
Nanobiotix resumed trading of its ordinary shares on Euronext Paris at 3:30 p.m. Paris time on May 21, 2026. According to Nanobiotix, this followed a temporary halt requested earlier the same day.
Why was Nanobiotix (NBTX) trading halted on Euronext Paris on May 21, 2026?
Trading in Nanobiotix ordinary shares was halted at the company’s request on May 21, 2026 from 9:00 a.m. CEST. According to Nanobiotix, the halt related to its previously announced Global Offering to confirm allocations and announce pricing.
What is the Global Offering mentioned in Nanobiotix (NBTX) May 21, 2026 trading update?
The Global Offering combines a U.S. public offering of ADSs with an international offering of ordinary shares and pre-funded warrants. According to Nanobiotix, the European tranche targets qualified investors in Europe and certain other countries, excluding the United States and Canada.
How does the Nanobiotix (NBTX) Global Offering relate to the May 21, 2026 trading halt?
The trading halt was connected to the company’s Global Offering process. According to Nanobiotix, the pause allowed time to confirm allocations to investors and prepare the announcement of the Global Offering pricing before normal trading resumed.
Where are Nanobiotix (NBTX) American Depositary Shares traded in relation to the May 2026 Global Offering?
Nanobiotix American Depositary Shares, each representing one ordinary share, are listed on Nasdaq under the symbol NBTX. According to Nanobiotix, the U.S. component of the Global Offering is a public offering of these ADSs in the United States.
